File(s) under permanent embargo
Reason: Under embargo until February 2022. After this date a copy can be supplied under Section 51(2) of the Australian Copyright Act 1968 by submitting a document delivery request through your library, or by emailing firstname.lastname@example.org
Neuroprotective mechanism of melatonin on ATP13A2-deficient Parkinson’s disease in vitro model: a proteomics analysis
thesisposted on 18.02.2021, 23:19 by YIING JYE YAP
Parkinson’s disease (PD) is second most common neurodegenerative disorder. Mutations in ATP13A2 gene have been implicated in familial forms of PD but the precise molecular mechanisms associated with the development of disease condition remain unknown. To address this question, ATP13A2-deficient in vitro PD model was developed to identify the dysregulated proteins that impaired autophagy and stress response pathways, which resulted in the imbalance of cellular redox and protein homeostasis. This study further explores the use of melatonin to rescue these changes in ATP13A2-deficient PD model. Indeed, melatonin was able to exert neuroprotective roles by regulating the pathogenic signalling pathways.